...
首页> 外文期刊>Diagnostic cytopathology >Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.
【24h】

Dipeptidyl aminopeptidase IV in the cytologic diagnosis of thyroid carcinoma.

机译:二肽氨基肽酶IV在甲状腺癌的细胞学诊断中的作用。

获取原文
获取原文并翻译 | 示例

摘要

Recently, the demonstration of DAP IV activity in thyroid cells aspirates has been proposed as an useful tool for the diagnosis of malignancy. We have studied the enzymatic activity of DAP IV, using the modified method of Lodja, in a series of 336 selected aspirates of the thyroid gland with the following cytologic diagnosis: 236 nodular hyperplasias, 60 follicular proliferations, eight Hashimoto's thyroiditis, eight Hurthe-cell proliferations, 20 papillary carcinomas, two anaplastic carcinomas, and two medullary carcinomas. The results were subjectively evaluated on the basis of staining intensity and extension in a minimum of 200 cells. Strong-to-moderate enzymatic activity with an extension of more than 40% of the cells were exclusively seen in follicular-cell derived carcinomas (papillary carcinoma, Hurthle-cell carcinoma, and follicular carcinoma). Medullary carcinoma, anaplastic carcinoma, and benign conditions were negative or weakly stained. Cytohistologic correlation in 88 patients operated on showed the following results: 26 nodular hyperplasia (18 nodular hyperplasia and eight follicular adenomas), 36 follicular proliferation (24 nodular hyperplasia, six, adenomas, three papillary carcinomas, three follicular carcinomas), two Hurthle-cell proliferation (one Hurthle-cell adenoma and one Hurthle-cell carcinoma), 20 papillary carcinomas, two medullary carcinomas, and two anaplastic carcinomas. DAP IV staining was moderate to strong and extensive in all malignant tumors initially diagnosed as follicular or Hurthle-cell proliferations. We conclude that DAP IV activity is present in malignant differentiated thyroid tumors of follicular cells (papillary carcinoma, follicular carcinoma, Hurthle-cell carcinoma), but it is identified neither in medullary carcinoma nor in anaplastic carcinoma. Therefore, its usefulness is restricted to the diagnosis of follicular-cell malignancies.
机译:最近,已提出在甲状腺细胞抽吸物中证明DAP IV活性是诊断恶性肿瘤的有用工具。我们使用改良的Lodja方法在一系列336例甲状腺腺抽吸物中研究了DAP IV的酶促活性,并进行了以下细胞学诊断:236结节性增生,60卵泡增生,8桥本甲状腺炎,8淋巴结细胞增生,20例乳头状癌,2例间变性癌和2例髓样癌。基于至少200个细胞的染色强度和延伸,主观评估结果。在滤泡细胞源性癌(乳头状癌,Hurthle细胞癌和滤泡性癌)中,仅见到强至中度的酶活性,且细胞扩展超过40%。髓样癌,间变性癌和良性疾病均为阴性或弱染色。 88例接受手术的患者的细胞组织学相关性显示以下结果:26个结节性增生(18个结节性增生和8个滤泡性腺瘤),36个滤泡增生(24个结节性增生,6个腺瘤,3个乳头状癌,3个滤泡性癌),两个Hurthle细胞增生(1个Hurthle细胞腺瘤和1个Hurthle细胞癌),20个乳头状癌,2个髓样癌和2个间变性癌。 DAP IV染色在最初被诊断为卵泡或Hurthle细胞增生的所有恶性肿瘤中为中等至强而广泛。我们得出的结论是DAP IV活性存在于滤泡细胞的恶性分化甲状腺肿瘤(乳头状癌,滤泡癌,Hurthle细胞癌)中,但在髓样癌和间变性癌中均未发现DAP IV活性。因此,其用途仅限于滤泡细胞恶性肿瘤的诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号